Nuclear Medicine
Francesco Ceci
-
-
02-57489.044
-
02-94379.223
-
Secretary email
-
highlight
The Division offers traditional nuclear medicine techniques as well as new diagnostic exams.
Our Activities
The Division of Nuclear Medicine is certified ISO 9001-2008 and is devoted to the early localization and treatment of tumors, by means of functional imaging and
targeted radionuclide therapy.
The Division offers traditional nuclear medicine techniques as well as new diagnostic exams, such as sentinel node lymphoscintigraphy in breast, gynecologic, tongue cancer and melanoma, radioguided occult lesion localisation (ROLL) in breast, lung and colon lesions, perfusion procedures in melanoma and sarcoma patients, peptide-guided whole body scans and PET scans. 18FDG-PET scans are routinely performed in the diagnosis, staging, follow up and radiotherapy planning of various types of
cancer, applying ROL criteria in PET/CT scan acquisition.
SinceJuly 2008 PET/TC scans with 68Ga-octreotide are performed. The Division is one of the few in Europe having protocols of radionuclide therapy of solid tumors and lymphomas with new radiolabelled molecules that show high affinity for tumor cells, such as monoclonal antibodies and radiolabelled peptides.
The Division has been one of the pioneers in the development of peptide receptor radionuclide therapy (PRRT) in NETs, where clinical studies have been carried out for over 15 years. Currently it is participating to an international registrative phase III study on PRRT. In 2013, 9685 diagnostic studies were performed, of which 4127 were PET/CT with 18FDG and 482 with 68Ga-octreotide, and over 650 outpatients were visited.
-
Our staff
Staff Nuclear Medicine
-
- High specialized physician Laura Lavinia Travaini
- Physician Francesco Mattana
- Physician Laura Gilardi
-
- Physician Marzia Colandrea
- Physician Paola Anna Rocca
- Physician Silvia Lidia Fracassi
-
- Physician Valentino Dragonetti
-
-
Clinical trials
IEO S685/112
A multicentre, stratified, open, randomized, comparator-controlled, parallelgroup phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumours
IEO S738
A phase 3, open-label, multicenter, randomized study of sequential Zevalin (ibritumomab tiuxetan) versus observation in patients at least 60 years of age with newly diagnosed diffuse large B-cell lymphoma in PET-negative complete remission after R-CHOP or R-CHOP-like therapy
IEO S 724/512
A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
-
publications











